Close Menu

NEW YORK (360Dx) – TearLab today announced it has submitted a 510(k) application to the US Food and Drug Administration for its TearLab Discovery Platform, an in vitro diagnostic testing system for ophthalmic conditions.

The submission also covers a test card measuring the inflammatory biomarker MMP-9, TearLab said, adding the TearLab Discovery platform will be able to perform its current FDA-cleared tear osmolarity test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.